type
interferon
ifn
respons
strong
crucial
moder
control
viral
infect
strength
system
illustr
fact
despit
temporari
discomfort
like
common
cold
diarrhea
viral
infect
caus
major
harm
healthi
immunocompet
host
achiev
immun
system
equip
wide
array
pattern
recognit
receptor
subsequ
coordin
type
ifn
respons
orchestr
plasmacytoid
dendrit
cell
pdc
convent
dendrit
cell
cdc
product
type
ifn
subtyp
dendrit
cell
dc
also
cell
crucial
execut
mani
antivir
process
despit
coordin
respons
morbid
mortal
still
common
viral
diseas
due
abil
virus
exploit
weak
immun
system
virus
success
evad
immun
infect
result
aberr
immun
respons
howev
weak
also
open
opportun
improv
via
clinic
intervent
seen
current
vaccin
antivir
treatment
program
applic
ifn
tolllik
receptor
ligand
dc
antivir
protein
investig
limit
viral
infect
unfortun
common
threat
stimul
immun
possibl
initi
aggrav
autoimmun
also
translat
anim
model
human
situat
remain
difficult
strengthsweaknessesopportunitiesthreat
swot
analysi
discuss
interact
host
viru
well
futur
therapeut
option
relat
type
ifn
system
centuri
infecti
diseas
common
caus
morbid
mortal
worldwid
due
achiev
like
vaccin
antimicrobi
drug
mani
infecti
diseas
prevent
control
strike
respect
develop
vaccin
smallpox
lethal
viru
global
claim
million
live
although
vaccin
procedur
alreadi
develop
centuri
last
end
centuri
world
declar
smallpoxfre
base
success
great
confid
viral
infect
could
conquer
definit
either
vaccin
antivir
drug
treatment
inspir
success
us
surgeon
gener
william
stewart
state
time
come
close
book
infecti
diseas
unfortun
futur
shown
otherwis
hiv
discov
aid
caus
agent
despit
massiv
effort
hiv
still
major
problem
worldwid
addit
rise
new
variant
virus
like
influenza
strain
sever
acut
respiratori
syndrom
corona
viru
sar
cov
potenti
pandem
threat
gener
realist
concern
furthermor
season
respiratori
viral
infect
variou
virus
caus
major
inconveni
healthi
peopl
lifethreaten
immunocompromis
thu
despit
vaccin
antivir
drug
viral
diseas
still
common
requir
develop
addit
therapeut
review
appli
strengthsweaknessesopportunitiesthreat
swot
analysi
discuss
virusimmun
interact
specul
im
possibl
use
interact
view
new
treatment
option
viru
abl
cross
first
barrier
like
skin
mucosa
strength
host
natur
defens
system
determin
outcom
infect
succeed
text
briefli
discuss
initi
key
step
involv
antivir
respons
see
also
figur
appropri
immun
respons
gener
viru
need
recogn
immun
cell
equip
differ
group
receptor
abl
sens
microbi
intrud
includ
virus
pattern
recognit
receptor
prr
recogn
pathogenassoci
molecular
pattern
pamp
fundament
differ
host
structur
one
first
discov
best
character
prr
tolllik
receptor
tlr
mostli
present
antigenpres
cell
like
macrophag
dendrit
cell
dc
also
nonimmun
cell
like
fibroblast
epitheli
cell
transmembran
receptor
locat
cell
surfac
endosom
cell
surfaceloc
tlr
recogn
mainli
lipid
protein
bacteria
yeast
virus
hand
intracellular
parasit
figur
schemat
overview
differ
signal
transduct
pathway
activ
plasmacytoid
dendrit
cell
pdc
convent
dendrit
cell
cdc
follow
viral
encount
gener
pdc
endocytos
viru
subsequ
tolllik
receptor
andor
stimul
interferon
respons
factor
activ
induc
transcript
ifnab
besid
execut
mani
antivir
function
autocrin
signal
via
interferon
ab
receptor
ifnar
also
induc
type
ifn
product
contrast
infect
endocytosi
cdc
result
activ
cytoplasm
pattern
recognit
receptor
accordingli
nuclear
factorkb
nfkb
facilit
transcript
ifnb
proinflammatori
cytokin
via
ifnar
activ
induc
product
type
ifnab
red
indic
major
rout
dot
arrow
indic
minor
rout
may
explain
endosom
local
viral
nucleic
acidrecogn
figur
also
endosom
locat
tlr
probabl
serv
ensur
toler
self
molecul
promot
ligand
access
interestingli
addit
wellknown
lipopolysaccharid
gramneg
bacteria
cell
surfac
tlr
also
associ
viral
recognit
shown
recogn
fusion
protein
rsv
likewis
next
recognit
gramposit
bacteria
involv
detect
variou
dna
virus
like
measl
viru
vaccinia
viru
cmv
interstingli
detect
seem
regul
especi
monocyt
addit
welldescrib
tlr
prr
also
play
import
role
viral
recognit
cytoplasm
prr
retino
acidinduc
gene
rigi
melanoma
differentiationassoci
gene
dnadepend
activ
ifnregulatori
factor
dai
recogn
viral
nucleic
acid
contrast
tlr
express
cell
rna
virus
differenti
recogn
rigi
activ
similar
pathway
figur
taken
togeth
innat
immun
system
equip
larg
varieti
prr
extend
array
essenti
sens
variou
microbi
compon
prevent
limit
viral
spread
much
possibl
implement
antivir
immun
convent
plasmacytoid
dendrit
cell
recognit
viru
celldepend
signal
cascad
initi
infect
nonimmun
cell
usual
result
detect
viral
dnarna
intermedi
cytoplasm
prr
product
ifnb
requir
limit
infect
antivir
cytokin
also
prime
cell
produc
type
ifn
compris
ifna
subtyp
ifnb
variou
ifn
type
essenti
initi
product
antivir
protein
dendrit
cell
better
equip
nonimmun
cell
initi
antivir
respons
convent
dendrit
cell
cdc
recogn
viral
invad
extracellular
tlr
clr
intracellular
prr
rigi
highli
express
cdc
figur
infect
nonimmun
cell
viral
nucleic
acid
need
detect
ifnb
type
ifn
produc
success
erad
control
viru
intervent
plasmacytoid
dendrit
cell
pdc
indispens
pdc
one
cell
express
figur
allow
detect
extend
repertoir
virus
initi
antivir
respons
virus
virusinfect
cell
first
intern
endocytosi
phagocytosi
respect
subsequ
recruit
endolysosom
pdc
acid
environ
disassembl
viru
viral
nucleic
acid
subsequ
recogn
ultim
massiv
amount
type
ifn
produc
contrast
cdc
nonimmun
cell
pdc
tlr
contribut
significantli
viral
recognit
cytoplasm
prr
rigi
consequ
pdc
less
depend
step
viral
life
cycl
recognit
significantli
acceler
respons
infect
dc
differ
respons
time
pdc
cdc
also
mark
differ
intracellular
signal
cascad
activ
follow
prr
stimul
cdc
viral
compon
stimul
tlr
apart
cytoplasm
prr
result
phosphoryl
interferonregulatori
factor
essenti
product
proinflammatori
cytokin
ifnb
first
wave
ifn
constitut
express
cdc
cell
type
next
autocrin
paracrin
signal
interferonab
receptor
ifnar
activ
lead
product
type
ifn
includ
variou
ifna
subtyp
second
wave
ifn
altern
pdc
constitut
express
activ
immedi
stimul
thu
prior
phosphoryl
autocrineparacrin
signal
requir
figur
accordingli
robust
antivir
respons
initi
contrast
respons
seen
cdc
rapid
character
product
high
amount
type
ifn
consequ
pdc
clearli
major
antivir
cell
type
due
rapid
abund
ifna
product
yet
cdc
indispens
clearanc
viral
infect
illustr
function
express
cdc
receptor
similar
pdc
also
recogn
viral
ssrna
interestingli
stimul
cdc
pdc
result
entir
differ
respons
although
pdc
produc
mainli
ifna
cdc
induc
proinflammatori
profil
nuclear
factorkb
nfkb
activ
product
tnfa
importantli
produc
figur
cytokin
augment
cytolyt
activ
natur
killer
nk
cell
also
induc
product
immunoregulatori
cytokin
ifng
nk
cell
thu
although
dc
subset
use
differ
antivir
pathway
certainli
mutual
exclus
respons
viral
infect
differ
cytokin
pattern
pdc
cdc
respond
collabor
viral
infect
connect
innat
adapt
immun
commun
cooper
two
dc
subset
vital
induc
appropri
immun
respons
toward
invad
pathogen
type
ifn
key
effector
molecul
innat
immun
system
essenti
antivir
respons
toward
plethora
virus
human
type
ifn
famili
compris
ifna
subtyp
ifnb
ifnk
ifn
ifnt
ifnd
molecul
engag
ubiquit
express
ifnar
bind
ifnar
stimul
interferonstimul
gene
isg
subsequ
induc
antivir
state
antivir
state
collect
term
limit
viral
replic
viral
resist
neighbor
cell
apoptosi
viral
infect
cell
although
ifnar
signal
induc
transcript
isg
surprisingli
gene
encod
protein
direct
antivir
effect
protein
target
virus
mani
differ
way
figur
interferon
also
induc
antivir
protein
term
restrict
factor
good
exampl
bone
marrow
stromal
protein
restrict
releas
fulli
form
progeni
virion
infect
cell
tetherin
protein
show
activ
variou
virus
includ
hiv
anoth
restrict
factor
apolipoprotein
b
mrnaedit
enzymecatalyt
polypeptidelik
lead
degrad
hiv
dna
restrict
factor
tripartit
motif
trim
seem
counteract
capsid
format
hiv
review
sastri
et
al
addit
mani
protein
stimul
type
ifn
involv
ifn
signal
rigi
tlr
therebi
amplifi
ifn
respons
posit
feedback
ifn
also
induc
modul
adapt
immun
respons
upregul
mhc
class
ii
facilit
b
cell
stimul
final
ifn
promot
leukocyt
accumul
site
infect
promot
vascular
adhes
molecul
express
induct
chemokin
essenti
leukocyt
recruit
recent
new
type
ifndepend
antivir
pathway
suggest
pedersen
et
al
demonstr
ifnb
rapidli
induc
express
sever
microrna
mirna
hepatocarcinoma
cell
line
huh
cell
primari
hepatocyt
small
noncod
rna
molecul
posttranscript
regul
inhibit
gene
express
translat
repress
mrna
cleavag
deadenyl
intriguingli
eight
ifnbinduc
mirna
show
sequencepredict
target
within
hcv
genom
rna
moreov
applic
synthet
mirnamim
result
antivir
effect
similar
induc
ifnb
wherea
antimirna
markedli
reduc
ifnbmedi
antivir
effect
addit
recent
shown
hepat
mirna
express
might
use
tool
predict
therapeut
outcom
pegyl
ifn
ribavirin
combin
therapi
emphas
potenti
role
mirna
ifnmedi
antivir
effect
conclus
presenc
wide
varieti
prr
enabl
detect
multipl
viral
ligand
present
infect
activ
prrdctype
ifn
axi
especi
axi
induc
rapid
respons
viru
mani
isg
divers
type
ifn
stimul
produc
respect
enabl
coordin
respons
variou
viral
infect
lead
control
elimin
viral
intrud
previou
section
describ
wellequip
immun
system
protect
host
viral
infect
nevertheless
virus
evad
influenc
immun
respons
target
certain
weak
immun
system
result
sever
diseas
strong
antivir
immunoregulatori
role
type
ifn
virus
develop
larg
varieti
antityp
ifn
mechan
consequ
nearli
step
type
ifn
pathway
block
manipul
differ
virus
benefit
altern
virusrel
morbid
mortal
due
virusinduc
immun
evas
facilit
extens
viral
replic
may
also
result
concomit
inappropri
exagger
respons
thu
increas
resist
antivir
effect
ifn
enhanc
viral
replic
evok
aberr
proinflammatori
respons
character
high
level
cytokin
chemokin
induc
pulmonari
injuri
observ
patient
likewis
devast
effect
hiv
infect
may
also
result
combin
hiv
infect
result
progress
immun
defici
impair
adapt
respons
low
cell
count
increas
suscept
opportunist
infect
one
earliest
find
aid
epidem
defici
ifna
product
hivinfect
patient
next
lower
number
ifnproduc
cell
also
cell
produc
less
ifna
respons
hiv
decreas
ifna
due
vpr
protein
hiv
strongli
inhibit
type
ifn
product
pdc
addit
effect
ifna
antagon
hiv
protein
vpu
induc
degrad
restrict
factor
howev
chronic
phase
hiv
infect
hypothes
ifna
contribut
declin
immun
system
induc
apoptosi
cell
noninfecti
interact
hivbound
protein
receptor
pdc
ifna
produc
result
kill
possibl
pdc
uninfect
cell
thu
although
apoptosi
infect
cell
usual
protect
mechan
prevent
viral
spread
result
distinct
advantag
viru
due
decreas
immun
control
cell
thu
despit
strength
type
ifn
system
virus
evolv
mechan
evad
manipul
system
guarante
surviv
among
other
predominantli
accomplish
interf
prr
signal
inhibit
activ
target
isg
search
therapi
led
develop
vaccin
antivir
drug
result
impress
reduct
virusrel
morbid
mortal
unfortun
vaccin
antivir
drug
suffici
prevent
control
viral
infect
make
imper
develop
novel
therapi
result
immunebas
therapi
current
develop
new
treatment
method
may
provid
new
opportun
treatment
acut
chronic
viral
infect
figur
plausibl
approach
treat
viral
infect
patient
administr
type
ifn
inde
pegyl
ifna
combin
antivir
drug
ribavirin
commonli
use
treat
patient
chronic
hcv
infect
although
therapi
effect
nearli
case
administr
pegyl
ifna
associ
sever
side
effect
normal
viral
infect
type
ifn
give
sicksign
result
fever
patient
treat
type
ifn
endur
feverish
period
prolong
period
time
addit
hematolog
psycholog
problem
frequent
report
treatment
period
also
respect
hiv
posit
effect
ifntreat
report
vitro
clinic
trial
hand
excess
ifna
contribut
immunopathogenesi
review
herbeuv
et
al
thu
remain
controversi
whether
ifna
benefici
detriment
hiv
underproduct
overproduct
ifna
induc
sever
effect
host
nonetheless
strong
antivir
effect
type
ifn
remain
attract
drug
antivir
therapi
particular
acut
respiratori
infect
ifn
may
interest
therapi
requir
system
chronic
applic
ifn
observ
hcv
patient
may
therefor
significantli
reduc
observ
side
effect
local
applic
exampl
nasal
spray
shown
effect
prevent
season
respiratori
infect
without
caus
sever
side
effect
administr
rout
might
particularli
attract
prevent
virusinduc
exacerb
chronic
obstruct
pulmonari
diseas
asthmat
patient
impair
ifn
product
may
import
mechan
contribut
virusinduc
exacerb
ifna
also
show
promis
effect
sever
acut
respiratori
syndrom
sar
import
induc
adequ
immun
respons
possibl
suppress
excess
inflammatori
respons
observ
sar
interestingli
also
member
ifn
famili
use
prevent
treat
viral
respiratori
infect
recent
discov
type
iii
ifn
show
strong
antivir
effect
respiratori
viral
infect
especi
given
prophylact
stimul
tlr
antigen
microbi
epitop
suffici
induc
fullblown
immun
respons
tlr
seem
like
target
antimicrobi
therapi
inde
synthet
variant
microbi
structur
shown
induc
natur
respons
without
need
infect
qualiti
use
extens
improv
efficaci
vaccin
exampl
vaccin
compos
mixtur
tlr
ligand
antigen
shown
effect
antigen
alon
moreov
tlr
ligand
coval
link
peptid
even
superior
abil
induc
specif
cell
direct
antivir
respons
requir
use
synthet
ligand
consid
vitro
vivo
studi
shown
prophylact
treatment
dsrna
mimic
polyinosin
polycytidyl
acid
poli
c
cpg
oligodeoxynucleotid
cpg
odn
specif
respect
protect
viral
infect
depend
viru
cell
type
differ
type
cpg
odn
appli
initi
appropri
respons
also
may
therapeut
target
stimul
tlr
imidazoquinolon
eg
resiquimod
imiquimod
best
known
ligand
small
molecular
weight
compound
inde
shown
possess
antivir
properti
although
immunostimulatori
antivir
effect
may
limit
compar
poli
c
cpg
odn
interestingli
use
imiquimod
cream
treat
human
papillomavirusinduc
genit
wart
alreadi
approv
tlr
ligand
also
reduc
hcv
viremia
even
hiv
could
target
besid
stimul
type
ifn
product
tlr
ligand
also
initi
immunoregulatori
mechan
particularli
import
gener
adapt
immun
respons
immunolog
memori
nonetheless
time
tlr
ligand
approv
clinic
applic
treat
viral
diseas
variou
viral
infect
pdc
cdc
less
function
present
lower
number
exampl
observ
hcvinfect
hivinfect
patient
number
pdc
partial
predict
clinic
outcom
therefor
adopt
transfer
pdc
cdc
use
reach
requir
level
pdc
subsequ
initi
type
ifn
respons
moreov
increas
efficaci
tlr
ligand
requir
appropri
receptor
predominantli
present
dc
shown
wang
et
al
adopt
transfer
pdc
use
success
activ
antivir
respons
limit
rsv
replic
thu
administr
stimul
pdc
concert
cdc
restor
dc
function
andor
number
activ
innat
immun
system
reach
requir
level
immun
activ
control
viral
infect
probabl
depend
individu
type
viral
infect
chronic
stage
infect
observ
mani
viral
infect
concomit
proinflammatori
respons
contribut
significantli
diseas
therefor
antiinflammatori
drug
attract
suppress
symptom
viral
diseas
also
use
antivir
drug
specif
inhibit
viral
replic
remain
attract
therapi
especi
combin
treatment
like
ifna
treatment
ribavirin
hcv
patient
furthermor
although
tlr
ligand
ifn
induc
product
restrict
factor
might
also
appli
directli
limit
viral
replic
hand
ifninhibitor
protein
virus
target
restor
immun
function
make
addit
restrict
factor
immunotherapi
effect
taken
togeth
although
virus
well
abl
subvert
manipul
type
ifn
respons
ifn
system
also
use
stimul
strengthen
respons
toward
viral
infect
ifn
alreadi
use
hcv
treatment
promis
effect
shown
respiratori
viral
infect
moreov
therapeut
use
tlr
ligand
current
intens
investig
shown
great
potenc
stimul
immun
cell
critic
involv
antivir
immun
respons
stimul
product
antivir
protein
inhibitor
viral
evas
protein
also
use
independ
tlr
stimul
ifn
applic
final
transfer
stimul
pdc
gradual
product
type
ifn
cytokin
combin
cdc
induct
adapt
immun
might
option
limit
symptom
even
control
viru
replic
previou
section
reveal
among
other
opportun
relat
tlr
ligand
potenti
antivir
drug
yet
although
promis
result
tlr
ligand
report
last
decad
also
sever
threat
endosom
tlr
usual
respond
dna
rna
deriv
pathogen
immun
respons
host
genet
materi
prevent
differ
way
first
dna
rna
apoptot
necrot
host
cell
remov
dnase
rnase
respect
second
nucleic
acid
microb
fundament
differ
host
nucleic
acid
viral
bacteri
dna
contain
unmethyl
cpg
motif
wherea
host
dna
heavi
methyl
fewer
cpg
motif
common
furthermor
tlr
bind
microbi
nucleic
acid
endosom
locat
intracellular
local
selfnucl
acid
stimul
tlr
final
regulatori
receptor
present
pdc
limit
type
ifn
respons
sometim
howev
barrier
suffici
aberr
immun
respons
aris
ultim
result
autoimmun
diseas
like
system
lupu
erythematosu
sle
autoimmun
disord
especi
affect
skin
sle
assum
apoptot
necrot
materi
contain
nucleic
acid
phagocytos
pdc
cdc
pdc
respond
product
type
ifn
cytokin
result
activ
cdc
stimul
autoreact
b
cell
differenti
b
cell
plasma
cell
autoantibodi
produc
complex
nucleic
acid
necrot
cell
subsequ
bind
fc
receptor
igg
fcgriia
pdc
cdc
result
type
ifn
product
bcell
stimul
viciou
cycl
evok
aggrav
administr
tlr
ligand
reason
pdc
respond
hostderiv
nucleic
acid
still
unclear
thu
concern
instig
enhanc
autoimmun
diseas
import
reason
tlr
ligand
extens
administ
clinic
despit
promis
result
last
decad
ligand
antivir
therapi
precautionari
measur
prevent
induc
autoimmun
respons
definit
necessari
much
know
come
anim
experi
translat
experiment
result
laboratori
anim
human
often
problemat
also
case
translat
knowledg
immun
respons
wellstudi
mous
model
human
exampl
respons
certain
virus
entir
differ
host
due
adapt
viru
host
moreov
import
differ
antivir
mechan
mice
human
observ
first
differ
tlrinduc
respons
studi
indic
murin
pdc
abl
produc
addit
ifna
stimul
wherea
human
pdc
secondli
locat
differ
mice
human
human
exclus
express
pdc
b
cell
mice
express
cdc
bcell
macrophag
monocyt
thu
ligand
induc
entir
differ
respons
speci
anoth
major
differ
function
stimul
induc
product
human
receptor
appear
nonfunct
mice
although
still
matter
debat
final
cytokin
ligand
use
differenti
murin
hematopoiet
stem
cell
dc
rel
high
percentag
pdc
reflect
human
situat
experi
perform
pbmc
contain
low
number
pdc
probabl
differ
stage
matur
henc
stimul
type
ifn
respons
improv
immun
toward
viral
infect
also
evok
aggrav
aberr
immun
respons
autoimmun
therebi
limit
clinic
applic
tlr
ligand
ifn
furthermor
although
anim
experi
extrem
help
deciph
antivir
respons
exact
represent
human
type
ifn
respons
hinder
clinic
applic
review
provid
condens
overview
molecular
pathway
involv
potent
antivir
part
innat
immun
system
type
ifn
respons
moreov
review
cell
receptor
intim
involv
type
ifn
system
also
evalu
im
possibl
new
way
modul
type
ifn
respons
exampl
tlr
ligand
adopt
dc
transfer
promis
futur
antivir
therapi
nonetheless
although
strong
antivir
effect
ifn
tlr
ligand
dc
restrict
factor
shown
mani
studi
clinic
applic
immunebas
therapi
unfortun
still
limit
might
relat
concern
eventu
undesir
side
effect
like
autoimmun
diseas
therefor
clinic
success
perhap
person
approach
requir
applic
immunebas
therapi
consid
base
individu
viru
stage
infect
symptom
therebi
finetun
type
ifn
respons
prevent
side
effect
much
possibl
author
compet
interest
